DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Metreleptin is an investigational drug.
There have been 22 clinical trials for Metreleptin. The most recent clinical trial was a Phase 2 trial, which was initiated on November 14th 2018.
The most common disease conditions in clinical trials are Lipodystrophy, Body Weight, and Non-alcoholic Fatty Liver Disease. The leading clinical trial sponsors are National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), AstraZeneca, and University of Michigan.
There are fifteen US patents protecting this investigational drug and three hundred and forty international patents.
Recent Clinical Trials for Metreleptin
|Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy||Aegerion Pharmaceuticals, Inc.||Phase 4|
|CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy||University of Michigan||Phase 2|
|Expanded Access Metreleptin Study||University of Michigan||Phase 2|
Top disease conditions for Metreleptin
Top clinical trial sponsors for Metreleptin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Metreleptin||Start Trial||Methods of treating obesity with two different anti-obesity agents||Amylin Pharmaceuticals LLC (San Diego, CA) AstraZeneca Pharmaceuticals LP (Wilmington, DE)||Start Trial|
|Metreleptin||Start Trial||FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same||Five Prime Therepeutics, Inc. (South San Francisco, CA)||Start Trial|
|Metreleptin||Start Trial||Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders||Sanofi (Paris, FR)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|